Budesonide/formoterol - Pearl Therapeutics

Drug Profile

Budesonide/formoterol - Pearl Therapeutics

Alternative Names: BFF MDI; Budesonide and formoterol (BFF MDI) - Pearl Therapeutics; Formoterol/budesonide - Pearl Therapeutics; PT-009

Latest Information Update: 21 Sep 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pearl Therapeutics
  • Class Antiasthmatics; Bronchodilators; Ethanolamines; Glucocorticoids; Pregnenediones; Small molecules
  • Mechanism of Action Beta 2 adrenergic receptor agonists; Glucocorticoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Chronic obstructive pulmonary disease

Most Recent Events

  • 16 Sep 2018 Adverse events and efficacy data from the phase III TELOS trial in Chronic obstructive pulmonary disease released by AstraZeneca
  • 15 Jun 2018 Pearl Therapeutics completes a phase III trial in Chronic obstructive pulmonary disease in Japan (Inhalation) (NCT03262012)
  • 17 May 2018 Pearl Therapeutics withdraws a phase III trial for Chronic obstructive pulmonary disease upon internal study team decision not to proceed (Inhalation) (NCT03081247)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top